High materiality8/10
Tandem Diabetes price target raised to $40 from $35 at Canaccord
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Target raised to $40; posted price $18.79; Canaccord Genuity; priceChangeSinceSignal 19.11.
- TNDM PT to $40 from Canaccord; price $18.79.
Key facts
- 01
Target: $40
- 02
Posted price: $18.79
- 03
Analyst firm: Canaccord Genuity
- 04
Analyst: William Plovanic
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.